BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Proleukin (aldesleukin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Proleukin (aldesleukin)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03546426-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Proleukin (aldesleukin): Phase 1 readout est. (NCT03546426)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1.\nStudy: Pembrolizumab Plus A
 utologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced 
 Mesothelioma Who Have Failed Prior Therapies\nEstimated primary completion
 : January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aldes
 leukin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03546426
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06237881-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT06237881)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2\, Melanoma.\nStudy: A Phase
  1/2 Study of KSQ-001EX\, Autologous Tumor Infiltrating Lymphocytes Engine
 ered to Inactivate the SOCS1 Gene\, in Patients With Select Advanced Solid
  Tumors\nEstimated primary completion: 1 January 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/aldesleukin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06237881
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05493566-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270107
DTEND;VALUE=DATE:20270108
SUMMARY:Proleukin (aldesleukin): Phase 1 readout est. (NCT05493566)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1.\nStudy: Low-Dose Interleukin
 -2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Can
 cer\nEstimated primary completion: 7 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/aldesleukin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05493566
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05267626-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT05267626)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2\, Melanoma.\nStudy: Study o
 f AU-007\, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα B
 inding\, in Patients With Unresectable Locally Advanced or Metastatic Canc
 er\nEstimated primary completion: 28 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/aldesleukin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05267626
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255664-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT07255664)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2.\nStudy: A FIH\, Phase I/II
 a\, Trial Assessing Feasibility of Administrations of TIL-based Immunother
 apy in Patients With Metastatic CRC and PC\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleuk
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7255664
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04166006-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Proleukin (aldesleukin): Phase 2 readout est. (NCT04166006)
DESCRIPTION:Proleukin (aldesleukin)\, phase 2.\nStudy: A Phase II Study on 
 Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Hom
 ogenate in Resected Stage IV Rare Cancers.\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleuk
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4166006
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05810792-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Proleukin (aldesleukin): Phase 2 readout est. (NCT05810792)
DESCRIPTION:Proleukin (aldesleukin)\, phase 2.\nStudy: Histamine Dihydrochl
 oride and Interleukin-2 in Primary Resectable Pancreatic Cancer\nEstimated
  primary completion: 1 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/aldesleukin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05810792
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05802056-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270424
DTEND;VALUE=DATE:20270425
SUMMARY:Proleukin (aldesleukin): Phase 1 readout est. (NCT05802056)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1.\nStudy: Aldesleukin With Niv
 olumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peri
 toneal Metastasis\nEstimated primary completion: 24 April 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/aldesleukin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05802056
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04263831-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT04263831)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2.\nStudy: Low Dose IL-2 for 
 the Treatment of Crohn's Disease\nEstimated primary completion: 30 June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleukin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04263831
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063875-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT07063875)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2\, Melanoma.\nStudy: Adding 
 IL-2 to Tebentafusp to Eradicate Cancer Progression\nEstimated primary com
 pletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/aldesleukin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07063875
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05821686-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT05821686)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2.\nStudy: Efficacy of Interl
 eukin-2 in Triple Negative Breast Cancer\nEstimated primary completion: Ap
 ril 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleukin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 21686
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468073-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280608
DTEND;VALUE=DATE:20280609
SUMMARY:Proleukin (aldesleukin): Phase 2 readout est. (NCT05468073)
DESCRIPTION:Proleukin (aldesleukin)\, phase 2.\nStudy: Therapeutic Evaluati
 on of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early
  AD\nEstimated primary completion: 8 June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/aldesleukin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05468073
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158828-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT06158828)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2.\nStudy: Pilot Study of Mem
 ory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploi
 dentical Transplant in AML\nEstimated primary completion: 15 September 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleukin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06158828
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700121-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Proleukin (aldesleukin): Phase 1 readout est. (NCT07700121)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1\, Melanoma.\nStudy: PICSTAT P
 ilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma
 \nEstimated primary completion: 1 October 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/aldesleukin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07700121
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610538-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Proleukin (aldesleukin): Phase na readout est. (NCT07610538)
DESCRIPTION:Proleukin (aldesleukin)\, phase na.\nStudy: Low-dose Interleuki
 n-2 After Myocardial Infarction to Investigate Effects on Tissue-resident 
 Regulatory T Cells\nEstimated primary completion: 1 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/aldesleukin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07610538
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904066-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Proleukin (aldesleukin): Phase 1 readout est. (NCT06904066)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1.\nStudy: Autologous T Cells T
 ransduced With Retroviral Vectors Expressing TCRs for Participant-specific
  Neoantigens in Patients With Hematologic Malignancies\nEstimated primary 
 completion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/aldesleukin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06904066
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01590069-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT01590069)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2\, Melanoma.\nStudy: Aerosol
 ized Aldesleukin in Treating Patients With Lung Metastases\nEstimated prim
 ary completion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/aldesleukin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT01590069
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651319-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT07651319)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2.\nStudy: Interleukine-2 (IL
 -2) Plus Semaglutide in Alzheimer's Disease\nEstimated primary completion:
  June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleuk
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7651319
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591649-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT07591649)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2.\nStudy: Adapt NK for High 
 Risk Myeloid Diseases as Bridge to Allo HSCT\nEstimated primary completion
 : 1 March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aldes
 leukin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07591649
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681596-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT07681596)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2.\nStudy: A Modular\, Phase 
 I/II\, Multicentre Study to Evaluate AZD4045\, in Participants With Relaps
 ed or Refractory Multiple Myeloma\nEstimated primary completion: 6 March 2
 031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleukin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07681596
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05155033-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20310901
DTEND;VALUE=DATE:20310902
SUMMARY:Proleukin (aldesleukin): Phase 2 readout est. (NCT05155033)
DESCRIPTION:Proleukin (aldesleukin)\, phase 2\, Renal Cell Carcinoma.\nStud
 y: Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic 
 Melanoma and Renal Cell Carcinoma\nEstimated primary completion: 1 Septemb
 er 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/aldesleukin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0515
 5033
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389239-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20311210
DTEND;VALUE=DATE:20311211
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT07389239)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2.\nStudy: A Study Evaluating
  the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Maligna
 ncies.\nEstimated primary completion: 10 December 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/aldesleukin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07389239
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06598371-5442@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20390801
DTEND;VALUE=DATE:20390802
SUMMARY:Proleukin (aldesleukin): Phase 1/2 readout est. (NCT06598371)
DESCRIPTION:Proleukin (aldesleukin)\, phase 1/2.\nStudy: A Phase 1/2 Study 
 of KSQ-004EX\, Autologous Tumor Infiltrating Lymphocytes Engineered to Ina
 ctivate Genes Encoding SOCS1 and Regnase-1\, in Patients With Select Advan
 ced Solid Tumors\nEstimated primary completion: 1 August 2039. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/aldesleukin#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06598371
URL:https://assetmemo.bio/drug/aldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
